Associated Papers
Pharmacogenetics of incretin-based therapies.
Yaluri AS et al.
Postgraduate Medical Journal, 2025
A multi-omics Mendelian randomization study reveals PAM as a potential therapeutic target for type 2 diabetes.
Yi M et al.
Journal of Translational Medicine, 2025
Peptidylglycine alpha-amidating monooxygenase is important in mice for beta-cell cilia formation and insulin secretion but promotes diabetes risk through beta-cell independent mechanisms.
Chen YC et al.
Molecular Metabolism, 2025
Deficiency of Peptidylglycine-alpha-amidating Monooxygenase, a Cause of Sarcopenic Diabetes Mellitus.
Giontella A et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists.
Umapathysivam MM et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion.
Trivellin G et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion.
Trivellin G et al.
Frontiers in Endocrinology, 2023
PAM variants in patients with thyrotrophinomas, cyclical Cushing's disease and prolactinomas.
De Sousa SMC et al.
Frontiers in Endocrinology, 2023
Gene-level analysis of rare variants in 379,066 whole exome sequences identifies an association of GIGYF1 loss of function with type 2 diabetes.
Deaton AM et al.
Scientific Reports, 2021
Exome sequencing and analysis of 454,787 UK Biobank participants.
Backman JD et al.
Nature, 2021
Rare Coding Variants Associated With Electrocardiographic Intervals Identify Monogenic Arrhythmia Susceptibility Genes: A Multi-Ancestry Analysis.
Choi SH et al.
Circulation. Genomic and Precision Medicine, 2021
Insights into pancreatic islet cell dysfunction from type 2 diabetes mellitus genetics.
Krentz NAJ et al.
Nature Reviews. Endocrinology, 2020
Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research.
Hu M et al.
Frontiers in Endocrinology, 2020
Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls.
Flannick J et al.
Nature, 2019
Type 2 diabetes risk alleles in PAM impact insulin release from human pancreatic β-cells.
Thomsen SK et al.
Nature Genetics, 2018
Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.
Xue A et al.
Nature Communications, 2018
The peptidylglycine-α-amidating monooxygenase (PAM) gene rs13175330 A>G polymorphism is associated with hypertension in a Korean population.
Yoo HJ et al.
Human Genomics, 2017
Recent progress in genetic and epigenetic research on type 2 diabetes.
Kwak SH et al.
Experimental & Molecular Medicine, 2016
Recent advances in understanding the genetic architecture of type 2 diabetes.
Mohlke KL et al.
Human Molecular Genetics, 2015
Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes.
Steinthorsdottir V et al.
Nature Genetics, 2014